Solid Tumors
Conditions
Keywords
Solid Tumors, veliparib, refractory, relapsed
Brief summary
Compare the bioavailability of three veliparib formulations in subjects with solid tumors.
Interventions
DRUGveliparib
veliparib formulation A
Sponsors
AbbVie
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Subjects with cytologically/histologically confirmed solid tumors that are either relapsed or refractory to standard therapy or there is no known effective therapy. 2. In the opinion of the Investigator, life expectancy is 12 weeks or greater. 3. Subjects with known brain metastases must have clinically controlled neurologic symptoms, defined as surgical excision and/or radiation therapy followed by 21 days of stable neurologic function and no evidence of central nervous system (CNS) disease progression as determined by computed tomography (CT) scan or magnetic resonance imaging (MRI) within 21 days prior to the first dose of study drug. 4. Subject has an Eastern Cooperative Oncology Group (ECOG) performance score of 0 to 2. 5. Subject must have adequate bone marrow, renal and hepatic function per local laboratory reference range.
Exclusion criteria
1. The subject is unable to swallow capsules or has nausea or vomiting. 2. Female subject is pregnant or breast-feeding. 3. Subject has a history of or an active medical condition(s) that affects absorption or motility (e.g., Crohn's disease, celiac disease, gastroparesis, short bowel syndrome). 4. History of gastric surgery, vagotomy, bowel resection (except for left hemicolectomy) or any surgical procedure that might interfere with gastrointestinal motility, potentiometric hydrogen ion concentration (pH) or absorption. 5. Subject exhibits evidence of other clinically significant uncontrolled condition(s) including, but not limited to: * Known seizure disorder that is uncontrolled over the past month * Active uncontrolled infection * Unstable angina pectoris or cardiac arrhythmia * Psychiatric illness/social situation that would limit compliance with study requirements
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Assess the oral bioavailability of veliparib | Up to 4 weeks. | Assess the relative bioavailability of Formulation A, Formulation B and Formulation C with or without food measured using area under the plasma concentration-time curve (AUC), the maximum observed plasma concentration (Cmax), and time to Cmax (Tmax). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| To evaluate the safety and tolerability of veliparib in patients with solid tumors | Up to 4 weeks | Safety and tolerability will be assessed through clinical laboratory tests, electrocardiograms (ECGs), vital signs, physical exams and adverse event assessments |
Outcome results
None listed